PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1227-1231

  Oliveira, J C ^a   Pezuk, J A ^b   Brassesco, M S ^b   Morales, A G ^b   Queiroz, R G P ^b   Scrideli, C A ^b   Tone, L G ^b  

^a FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BI 2536; Cell cycle; Childhood acute lymphoblastic leukemia; PLK1 expression

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; COMPLEMENTARY DNA; MESSENGER RNA; POLO LIKE KINASE 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BI 2536; CELL CYCLE; CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA; PLK1 EXPRESSION;

ADOLESCENT; BONE MARROW; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; JURKAT CELLS; M PHASE CELL CYCLE CHECKPOINTS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84899686908     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24978     Document Type: Article

References (31)

1. Pui CH. Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 2010; 109:777-787.
2. Strebhardt K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-660.
3. Cheng MW, Wang BC, Weng ZQ, et al. Clinicopathological significance of polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochem 2012; 114:503-509.
4. Evans RP, Dueck G, Sidhu R, et al. Expression, adverse prognostic significance and therapeutic small molecule inhibition of polo-like kinase 1 in multiple myeloma. Leuk Res 2011; 35:1637-1643.
5. He ZL, Zheng H, Lin H, et al. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 2009; 15:4177-4182.
6. Stone A, Cowley MJ, Valdes-Mora F, et al. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol Cancer Ther 2013; 12:1874-1885.
7. Wang R, Song Y, Xu X, et al. The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival. Clin Transl Oncol 2013; 15:626-632.
8. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009; 23:1564-1576.
9. Brandalise SR, Pinheiro VR, Aguiar SS, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: Randomized trial from the Brazilian Childhood Cooperative Group-protocol ALL-99. J Clin Oncol 2010; 28:1911-1918.
10. Scrideli CA, Assumpcao JG, Ganazza MA, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009; 94:781-789.
11. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13:1901-1928.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25:402-408.
13. Schmit TL, Zhong W, Setaluri V, et al. Targeted depletion of polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129:2843-2853.
14. Han DP, Zhu QL, Cui JT, et al. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit 2012; 18:BR237-246.
15. Schmit TL, Zhong W, Nihal M, et al. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 2009; 8:2697-2702.
16. Weichert W, Schmidt M, Gekeler V, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60:240-245.
17. Weichert W, Schmidt M, Jacob J, et al. Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005; 5:259-265.
18. Zhang G, Zhang Z, Liu Z. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumour Biol 2013; 34:1887-1894.
19. Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol 2013; 31:1222-1230.
20. Ross DT, Perou CM. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers 2001; 17:99-109.
21. Virtanen C, Ishikawa Y, Honjoh D, et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci U S A 2002; 99:12357-12362.
22. Brassesco MS, Pezuk JA, Morales AG, et al. In vitro targeting of polo-like kinase 1 in bladder carcinoma: Comparative effects of four potent inhibitors. Cancer Biol Ther 2013; 14:648-657.
23. de Oliveira JC, Brassesco MS, Pezuk JA, et al. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol 2012; 11:587-592.
24. Morales AG, Brassesco MS, Pezuk JA, et al. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 2011; 22:995-1001.
25. Pezuk JA, Brassesco MS, Morales AG, et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Ther 2013; 20:499-506.
26. Spaniol K, Boos J, Lanvers-Kaminsky C. An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. Anticancer Drugs 2011; 22:531-542.
27. Gorlick R, Kolb EA, Keir ST, et al. Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2014; 61:158-164.
28. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009; 14:559-570.
29. McInnes C, Wyatt MD. PLK1 as an oncology target: Current status and future potential. Drug Discov Today 2011; 16:619-625.
30. Hofheinz RD, Al-Batran SE, Hochhaus A, et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 16:4666-4674.
31. Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 2011; 17:6459-6466.